Abstract
The previous years, the incidence of lung adenocarcinoma (LADC) has gradually increased. As a subset of non-small cell lung cancer (NSCLC), LADC is very severe (12% 5-year survival rate) and often occurs in people who have never smoked. With forward genetic research, scientists have found a series of related mutant genes. Among them, EGFR is the most common gene mutation in Asian LADC. This article systematically summarizes and analyzes the existing treatment methods and related clinical data for EGFR mutations in LADC and puts forward the prospect of feasible treatment methods in the future. This includes traditional chemotherapy and radiotherapy, targeted drug therapy (fifth generation and FDA-approved drugs), and immunotherapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
